7.47
3.24%
-0.25
Dopo l'orario di chiusura:
7.20
-0.27
-3.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
(COGT) Trading Advice - Stock Traders Daily
Stock Traders Daily
Cogent Biosciences, Inc. Expected to Post Q2 2024 Earnings of ($0.60) Per Share (NASDAQ:COGT) - Defense World
Defense World
Investor's Toolkit: Key Ratios for Assessing Cogent Biosciences Inc (COGT)'s Performance – DWinneX - The Dwinnex
The Dwinnex
HC Wainwright Weighs in on Cogent Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:COGT) - MarketBeat
MarketBeat
Take off with Cogent Biosciences Inc (COGT): Get ready for trading – Sete News - SETE News
SETE News
Cogent Biosciences (NASDAQ:COGT) Rating Reiterated by HC Wainwright - Defense World
Defense World
Cogent Biosciences Inc (COGT) stock: A year of ups and downs – US Post News - US Post News
US Post News
Cogent Biosciences' (COGT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
MarketBeat
We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth - Yahoo Finance
Yahoo Finance
Cogent Biosciences' (COGT) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Defense World
Cogent Biosciences (COGT) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Fisher Asset Management LLC - Defense World
Defense World
Wedbush Comments on Cogent Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:COGT) - Defense World
Defense World
Q2 2024 Earnings Estimate for Cogent Biosciences, Inc. (NASDAQ:COGT) Issued By Leerink Partnrs - Defense World
Defense World
Cogent Biosciences, Inc. to Post Q2 2024 Earnings of ($0.66) Per Share, Leerink Partnrs Forecasts (NASDAQ:COGT) - MarketBeat
MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Buys 7606 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $13.67 Consensus PT from Brokerages - MarketBeat
MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Defense World
Cogent Biosciences (NASDAQ:COGT) Issues Quarterly Earnings Results - MarketBeat
MarketBeat
Cogent Biosciences (NASDAQ:COGT) Receives Buy Rating from Needham & Company LLC - MarketBeat
MarketBeat
Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewswire
GlobeNewswire
Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewswire
GlobeNewswire
(COGT) Investment Report - Stock Traders Daily
Stock Traders Daily
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR ... - GlobeNewswire
GlobeNewswire
5 Best Medical Stocks to Buy Under $10 - Insider Monkey
Insider Monkey
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance
Yahoo Finance
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
GlobeNewswire Inc.
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with ... - Yahoo Finance
Yahoo Finance
5 Best Booming Stocks to Buy Right Now - Insider Monkey
Insider Monkey
Cogent Biosciences Launches $225M Private Stock Sale - TipRanks.com - TipRanks
TipRanks
Steven Cohen's Point72 Asset Management Bolsters Position in Cogent Biosciences - Yahoo Finance
Yahoo Finance
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst (COGT) - Seeking Alpha
Seeking Alpha
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
GlobeNewswire Inc.
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and ... - Yahoo Finance
Yahoo Finance
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Analyst Expectations for Cogent Biosciences's Future
Benzinga
Nasdaq Edges Higher; Macy's Shares Jump
Benzinga
Dow Surges 100 Points; Cogent Biosciences Shares Plunge
Benzinga
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
Benzinga
US Stocks Mixed; Cigna Shares Spike Higher
Benzinga
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
GlobeNewswire Inc.
ASH 2023: Phase II case Cogent enough with bezu in mastocytosis? Street skeptical, more data soon - BioWorld Online
BioWorld Online
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
GlobeNewswire Inc.
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients ... - GlobeNewswire
GlobeNewswire
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium - GlobeNewswire
GlobeNewswire
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Yahoo Finance
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI ... - GlobeNewswire
GlobeNewswire
Capitalizzazione:
|
Volume (24 ore):